

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	20 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund & David & Elisabeth Brookes atf Dahlbrook Family Trust
Date of change	Ordinary Shares: 8 December 2023
No. of securities held prior to change	Direct: Ordinary Shares: 350,000 Ordinary Shares Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023 expire 14 November 2025; and 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 1,242,858 Ordinary Shares and 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025 David & Elisabeth Brookes atf Dahlbrook Family Trust 571,428 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Ordinary Shares
Number acquired	Direct – David Brookes 140,000 Ordinary Shares = \$3,080 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 497,144 Ordinary Shares = \$10,937.17 & David & Elisabeth Brookes atf Dahlbrook Family Trust 228,572 Ordinary Shares = \$5,028.59
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$19,045.76
No. of securities held after change	Direct: Ordinary Shares: 490,000 Ordinary Shares Options: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023 expire 14 November 2025; and 175,000 Options exercisable at \$0.07 ea expiring 11 December 2025 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 1,740,002 Ordinary Shares and 396,429 Options exercisable at \$0.07 ea expiring 11 December 2025 David & Elisabeth Brookes atf Dahlbrook Family Trust 800,000 Ordinary Shares and 285,714 Options exercisable at \$0.07 ea expiring 11 December 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Ordinary Shares at \$0.022 each purchased under the Entitlement Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.